SCHEMBL12439243

SCHEMBL12439243

CC(C)(C)OC(=O)NS(=O)(=O)NCC(O)c1cc(Cl)ccc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 4/20 0.47
CA14 Q9ULX7 3/20 0.47
CA1 P00915 2/20 0.47
CA7 P43166 1/20 0.47
CA2 P00918 2/20 0.46
HSP90AA1 P07900 1/20 0.38
HSP90AB1 P08238 1/20 0.38
IDO1 P14902 2/20 0.38
CA9 Q16790 1/20 0.37
ALDH1A1 P00352 2/20 0.37
MAPT P10636 2/20 0.37
HPGD P15428 2/20 0.37
TP53 P04637 2/20 0.37
GLA P06280 1/20 0.37
XBP1 P17861 1/20 0.37
HTT P42858 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
HSD17B10 Q99714 1/20 0.37
KDM4E B2RXH2 1/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12438458 0.86 CA12 (0.55) CA12CA14CA1CA7CA2
SCHEMBL12439242 0.82 CA12 (0.50) CA12CA14CA1CA7CA2
SCHEMBL12439239 0.77 CA12 (0.55) CA12CA14CA1CA7CA2
SCHEMBL2322723 0.73 CA2 (0.39) CA12CA1CA2CA9ALDH1A1
SCHEMBL14148346 0.73 CA12 (0.50) CA12CA14CA1CA7CA2
SCHEMBL6340981 0.73 CA12 (0.75) CA12CA14CA1CA7CA2
SCHEMBL12438380 0.73 CA12 (0.50) CA12CA14CA1CA7CA2
SCHEMBL8173578 0.71 CA12 (0.56) CA12CA14CA1CA7CA2
SCHEMBL14148327 0.70 CA12 (0.50) CA12CA14CA1CA7CA2
SCHEMBL12322196 0.70 IDO1 (0.43) IDO1ALDH1A1MAPTHPGDTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120302546-A1 NOVEL SULFAMIDES EXHIBITING NEUROPROTECTIVE ACTION AND METHODS FOR USE THEREOF FOX CHASE CHEMICAL DIVERSITY CENTER, INC. (US) 2012-11-29 US disclosed
WO-2011097337-A1 NOVEL SULFAMIDES EXHIBITING NEUROPROTECTIVE ACTION AND METHODS FOR USE THEREOF ADVANCED NEURAL DYNAMICS, INC. (US) 2011-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302546-A1 NOVEL SULFAMIDES EXHIBITING NEUROPROTECTIVE ACTION AND METHODS FOR USE THEREOF GRIK2, GRIK5, GRIN2A CA12 750/4885CA14 1699/4885CA1 116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.